When the UK leaves the European Union at the end of the Brexit
Transition Period, 31st December 2020, our primary aim is to ensure
this does not impact patient access to our medicines.
We understand this change may cause uncertainty for individuals and
would like to reassure those concerned about the many
steps AbbVie has taken to prepare for the 1st January 2021:
- Following the UK’s decision to leave the European Union AbbVie
has been working with a range of stakeholders across the UK and
Europe to take all the necessary steps to plan for undisrupted
supply of medicine to patients at the end of the transition
- We have completed a number of supply, logistics and
procedural activities to ensure we continue to meet our obligations
to UK and EU regulatory bodies and authorities
- We have
developed robust contingency plans and continue to update these as
need dictates. These plans cover the range of our activities
including the supply of medicines, clinical research and medicine
development activity and all steps to support patient safety
AbbVie is following the advice of the UK Government and EU
authorities and working with the NHS, amongst others, on these plans.
If you have any concerns relating to your own situation and any
medicine(s) you may have been prescribed, it is
recommended that you engage with your healthcare team on these matters.